Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Story being shared
FDA warns against aliskiren combos for diabetes and kidney patients
Combining aliskiren with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers might lead to renal impairment, hypotension and hyperkalemia in patients with diabetes, the FDA said. The agency also advised patients with renal impairment to avoid such a combination.
Or we can send an email on your behalf